Newsfeeds Archive - Page 7 of 7

1 minute read

FDA
News

AIM Immunotech Announces Commencement Of Phase 2 Study Of Ampligen For The Treatment Of Pancreatic Cancer

August 18, 9:05 AM

AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune

AIM

1 minute read

Earnings

Recap: AIM ImmunoTech Q2 Earnings

By Benzinga Insights

August 15, 10:23 AM

AIM ImmunoTech (AMEX:AIM) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

AIM

1 minute read

AIM ImmunoTech Q2 EPS $(0.10) Up From $(0.12) YoY

By Bill Haddad

August 15, 8:16 AM

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.

AIM

2 minute read

Earnings

Earnings Scheduled For August 12, 2022

By Benzinga Insights

August 12, 4:42 AM

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

AIM

3 minute read

Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket

By Lisa Levin

August 1, 6:43 AM

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.

AEMD

4 minute read

AIM ImmunoTech Reports Positive Pilot Study Data From Expanded Access Program Evaluating Ampligen For The Treatment Of Long COVID-19

By Michael Horton

July 28, 9:11 AM

AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune

AIM

1 minute read

AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study

By Vandana Singh

July 20, 11:31 AM

AIM ImmunoTech Inc (NYSE:AIM) reported follow-on data from its published single-center named patient program. For the study, patients with locally advanced…

AIM

1 minute read

AIM ImmunoTech Reports Additional Patient Data From Single-center Named Patient Program Evaluating Ampligen As Maintenance Therapy For Advanced Pancreatic Cancer Indicating Additional Progression-free And Overall Survival Over Previously Published Data

By Benzinga Newsdesk

July 20, 8:09 AM

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data

AIM

1 minute read

News

AIM ImmunoTech Announces That Recently Received Director Nominations From Jorgl Activist Group Are Invalid

By Benzinga Newsdesk

July 18, 8:07 AM

Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities

AIM

3 minute read

This Healthcare Stock is Surging By Over 21%: Here’s 24 Biggest Movers In Tuesday’s Pre-Market

By Lisa Levin

July 12, 6:14 AM

Gainers Versus Systems Inc. (NASDAQ: VS) rose 66% to $0.7802 in pre-market trading. Versus Systems, last month, received NASDAQ notification regarding minimum bid price deficiency.

ACRX